Here are the S-1 registration statements from Scilex Holding Company (SCLX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow SCLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCLX filings page.
Scilex Holding Company has filed a preliminary S-1 shelf registration to register up to 500,000 shares of common stock issuable upon exercise of Exchange Warrants and up to 1,703,946 shares of common stock for resale by selling stockholders.
The warrant-related shares come from prior financing, exchange and inducement agreements involving October 2024 Noteholder Warrants, December 2024 RDO Common Warrants and 2025 warrant issuances, and Scilex will receive cash only if the Exchange Warrants, September 2025 Warrants or November 2025 Warrants are exercised.
Scilex, listed on the Nasdaq Capital Market under the symbol SCLX, focuses on non-opioid pain management with three commercial products, ZTlido, ELYXYB and GLOPERBA, plus three late-stage product candidates for sciatica, acute low back pain and fibromyalgia. The company effected a 1-for-35 reverse stock split in April 2025 and highlights substantial risks related to its business and this offering in the Risk Factors section.